Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 OC7.2 | DOI: 10.1530/endoabs.56.OC7.2

1Mayo Clinic, Rochester, USA; 2University of Birmingham, Birmingham, UK; 3University of Turin, Turin, Italy; 4University of Wuerzburg, Wuerzburg, Germany; 5Endocrinology Charlottenburg, Berlin, Germany; 6University Hospital, Zagreb, Croatia; 7Evangelismos Hospital, Athens, Greece; 8Ludwig-Maximilians-University, Munich, Germany; 9University of Zuerich, Zuerich, Switzerland; 10Medical University of Warsaw, Warsaw, Poland; 11University of Groningen, Groningen, Netherlands.


Background: Adrenal masses are discovered in 5% of abdominal imaging scans. Accuracy of currently available imaging tests to diagnose malignancy is poor. In a proof-of-concept study (JCE&M 2011;96(12):3775-84), we had demonstrated 90% sensitivity and specificity in detecting adrenocortical carcinoma (ACC) for urine steroid metabolomics, the combination of mass spectrometry-based steroid profiling and machine learning-based data analysis. This diagnostic performance is superior to costly imaging procedures currently used for differentiating benign from malignant adrenal masses, which lead to a high rate of unnecessary surgery. Implementation of our novel test in routine practice requires prospective validation.

Methods: We undertook a prospective multi-center international test validation study, powered to achieve recruitment of 2000 patients with an anticipated ACC rate of 5%, with prospective recruitment of patients with newly diagnosed adrenal mass >5 mm, biochemical exclusion of pheochromocytoma and 24-h urine collection; recruitment was carried out in 13 centers (11 countries) of the European Network for the Study of Adrenal Tumors (ENSAT). Urinary steroid excretion was quantified by high-throughput liquid chromatography-tandem mass spectrometry and results processed by an algorithm based on generalized matrix relevance learning vector quantization (GMLVQ). Reference standard (benign/malignant) was based on histology and imaging follow-up.

Results: We enrolled 2017 patients, 1767 (87.6%) with a benign adrenocortical adenoma (ACA), 98 (4.9%) with ACC, and 87 (4.3%) and 65 (3.2%) with other benign and malignant adrenal masses, respectively. Risk of ACC was highest in patients <40 years (13%; vs 4% in >40 years, P<0.0001) and adrenal masses >4 cm (20%; vs 0.13% in <4 cm, P<0.0001). Unenhanced CT imaging of the adrenal mass was available for 1328/1767 patients with ACA; 68% of masses had a radiodensity <10 HU indicative of a benign lesion; 17% had borderline results (10–20 HU) and 15% were suspicious of ACC (>20 HU). MRI with chemical shift indicated suspicion of ACC in 22% of 273 benign ACA. Adrenalectomy was performed in 21% (370/1767) of ACA patients. Urine steroid metabolomics demonstrated an excellent diagnostic performance with AUROC of 94.6% for 15 steroids (Sens=Spec 87.1%).

Conclusions: Overall risk of ACC in adrenal tumors is 4.9% and almost exclusively relates to adrenal masses >4 cm. ACAs are frequently misclassified as malignant by routine imaging, resulting in a high rate of imaging and unnecessary adrenalectomies. Urine steroid metabolomics demonstrates high accuracy for detection of ACC and should become standard-of-care in patients with indeterminate adrenal tumors.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.